Results of Operations and Financial Condition. On July 30, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2026 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise…

The filing is about an amendment to the stock incentive plan, not a management change.

Results of Operations and Financial Condition. On April 29, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended March 31, 2026 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwis…

Results of Operations and Financial Condition. On February 12, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter and year ended December 31, 2025 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Results of Operations and Financial Condition. On October 30, 2025, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended September 30, 2025 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or ot…

Results of Operations and Financial Condition. On July 31, 2025, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2025 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise…

Director — Jay Backstrom, M.D., MPH: Dr. Jay Backstrom was elected as a director and appointed to the Science and Technology Committee.

The filing pertains to an amendment of the stock incentive plan, not a management change.

Results of Operations and Financial Condition. On May 1, 2025, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended March 31, 2025 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise s…

Results of Operations and Financial Condition. On February 13, 2025, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter and year ended December 31, 2024 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Director — David P. Schenkein, M.D.: Dr. Schenkein resigned from the Board of Directors and will no longer serve as a member of the Science and Technology Committee.

Results of Operations and Financial Condition. On October 31, 2024, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended September 30, 2024 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or ot…

Results of Operations and Financial Condition. On August 1, 2024, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2024 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise…

Entry into a Material Definitive Agreement. On May 24, 2024, Agios Pharmaceuticals, Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV, an Irish collective management vehicle (the “Purchaser”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchaser, and the Purchaser agreed to purchase for $905,000,000, the Company’s rights to an earn-out equal to 15% of U.S. net sales of vorasidenib (th…

Results of Operations and Financial Condition. On May 2, 2024, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended March 31, 2024 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise s…

Results of Operations and Financial Condition. On February 15, 2024, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter and year ended December 31, 2023 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Results of Operations and Financial Condition. On November 2, 2023, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended September 30, 2023 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or ot…

Results of Operations and Financial Condition. On August 3, 2023, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2023 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise…

Director — John Maraganore, Ph.D.: Dr. Maraganore resigned from the Board after nearly 12 years of service.

Results of Operations and Financial Condition. On May 4, 2023, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended March 31, 2023 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise s…

Director — Paul Clancy: Paul Clancy decided not to stand for re-election as a director, and Jeff Capello was elected as his successor.

Results of Operations and Financial Condition. On February 23, 2023, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter and year ended December 31, 2022 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

The filing describes a new performance-based cash bonus plan for certain executives.

Chief Commercial Officer — Tsveta Milanova: Appointment of a new Chief Commercial Officer.

Results of Operations and Financial Condition. On November 3, 2022, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended September 30, 2022 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or ot…